Imaging Response to Contemporary Immuno-oncology Combination Therapies in Patients With Metastatic Renal Cell Carcinoma
Authors:
Open Access
- 10 June 2022
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 5 (6) , e2216379
Abstract
Improvements in overall survival (OS) among patients with metastatic renal cell carcinoma (mRCC) have been achieved by combination therapy approaches using agents targeting immune checkpoint blockade (ICB) and the vascular endothelial growth factor (VEGF) receptor.1 Patients and physicians have numerous first-line immuno-oncology (IO) treatment options, including doublet ICB therapy with ipilimumab-nivolumab (IOIO) or ICB therapy with VEGF receptor inhibitor (IOVE; including axitinib-avelumab, axitinib-pembrolizumab, cabozantinib-nivolumab, and lenvatinib-pembrolizumab) combination therapies. However, most patients eventually develop resistance to these therapies.2Keywords
This publication has 37 references indexed in Scilit:
- Evaluation of Overall Response Rate and Progression-Free Survival as Potential Surrogate Endpoints for Overall Survival in Immunotherapy TrialsClinical Cancer Research, 2018
- Clinical Impact of Pancreatic Metastases from Renal Cell Carcinoma: A Multicenter Retrospective AnalysisPLOS ONE, 2016
- Effect of glandular metastases on overall survival of patients with metastatic clear cell renal cell carcinoma in the antiangiogenic therapy eraUrologic Oncology: Seminars and Original Investigations, 2016
- Impact of Bone and Liver Metastases on Patients with Renal Cell Carcinoma Treated with Targeted TherapyEuropean Urology, 2014
- Reviews Spontaneous regression of renal cell carcinomaContemporary Oncology, 2013
- Distribution of metastatic sites in renal cell carcinoma: a population-based analysisAnnals of Oncology, 2011
- Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter StudyJournal of Clinical Oncology, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- When You Look Matters: The Effect of Assessment Schedule on Progression-Free SurvivalJNCI: Journal of the National Cancer Institute, 2007
- Cytoreductive Nephrectomy in Patients With Metastatic Renal Cancer: A Combined AnalysisJournal of Urology, 2004